EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment

Cheng Wang, Xin Wang, Xiaoxue Wang, Baorui Tian, Sihe Zhang, Tianqi Wang, Yakun Ma, Yan Fan

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2023.107004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Cheng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tia…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we identified a newly synthesized compound 7o with potent inhibition on EGFR primary mutants (L858R, Del19) and drug-resistant mutant T790M with nanomolar IC50 values. 7o showed strong antiproliferative effects against EGFR mutant-driven non-small cell lung cancer (NSCLC) cells such as H1975, PC-9 and HCC827, over cells expressing EGFRWT. Molecular docking was performed to investigate the possible binding modes of 7o inside the binding site of EGFRL858R/T790M and EGFRWT. Analysis of cell cycle evidenced that 7o induced cell cycle arrest in G1 phases in the EGFR mutant cells, H1975 and PC-9, which resulted in decreased S-phase populations. Moreover, compound 7o induced cancer cell apoptosis in in vitro assays. In addition, 7o inhibited cellular phosphorylation of EGFR. In vivo, oral administration of 7o caused rapid tumor regression in H1975 xenograft model. Therefore, 7o might deserve further optimization as cancer treatment agent for EGFR mutant-driven NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansErbB ReceptorsMolecular Docking SimulationCell ProliferationProtein Kinase InhibitorsMutationCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

Del19EGFRInhibitorL858RT790M

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China.
  • School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.
  • Eye Institute, Nankai University, 94 Weijin Road, Tianjin 300071, China; School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China. Electronic address: yanfan@nankai.edu.cn.

Zitieren

APA

Wang, C., Wang, X., Wang, X., Tian, B., Zhang, S., Wang, T., Ma, Y., & Fan, Y. (2024). Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2023.107004

Vancouver

Wang C, Wang X, Wang X, Tian B, Zhang S, Wang T, et al. Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2023.107004

BibTeX
@article{Wang2024,
  author = {Wang, Cheng and Wang, Xin and Wang, Xiaoxue and Tian, Baorui and Zhang, Sihe and Wang, Tianqi and Ma, Yakun and Fan, Yan},
  title = {Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2023.107004}
}
Kostenlos starten →